ASH News Daily - Sunday, December 11, 2011 - (Page A-5)

Sunday, December 11, 2011 ASH/EHA Raising Awareness for Global Vaccines By david gaRcia, Md, and ShaRi ghanny, Md that 33 million people are living with HIV, the worst affected region being sub-Saharan Africa. According to the WHO, in 2005, just over 14 percent of all new HIV infections occurred in children under 15 years of age. Although great advances have been made in the treatment of HIV infection with the use of com- I n 1981, the first cases of AIDS began to emerge in the United States. Currently, it is estimated bination anti-retroviral therapy, the virus’s elegant design and its ability to evade the host’s immune system has been the focus of scientific research for years. This and other global health vaccines will be the focus of this afternoon’s ASH/ EHA Joint Symposium. In 2003, the Global HIV Vaccine Enterprise was created as a worldwide collaborative effort that includes more than 30 independent organizations committed to the research and development of a preventive HIV vaccine. The founda- tion of the Enterprise stems from its Scientific Strategic Plan, a framework upon which the Enterprise Council could share, expand, and execute its vision. The Plan includes reports from five working groups, highlighting the collaborative and multi-disciplinary approach needed for this endeavor: Immunogens and Antigen Processing; Host Genetics and HIV Diversity; Novel Approaches to HIV Vaccine Research & Development; Bridging the Gaps between Fundamental, Preclinical, and Clinical Research; and Young and Early Career Investigators. In 2010, the Plan was updated to prioritize objectives required to integrate pre-clinical and clinical research. When asked about his thoughts on the progress and challenges of vaccines for global health, former Executive Director of the Global HIV Vaccine Enterprise and main speaker at this afternoon’s symposium, Dr. Alan Bernstein responded: “These are exciting times in global health. Vaccines are unquestionably »» GLOBAL VACCINES Page A-16 ASH NEWS DAILY Page A–5 ® Locate the mutation. Stay one step ahead of CML resistance. Register at booth #503 or visit www.CMLResponseProject.com. ©2011 ARIAD Pharmaceuticals, Inc. All rights reserved. 5343311 REGISTER AT BOOTH #503 21425 ARIA ASH Program Ad_Mv1.indd 1 10/14/11 11:50 AM

Table of Contents for the Digital Edition of ASH News Daily - Sunday, December 11, 2011

ASH News Daily - Sunday, December 11, 2011

https://www.nxtbookmedia.com